Onglyza

Promised: Diabetes Treatment Without Weight Gain

Onglyza (saxagliptin) was approved by the U.S. Food and Drug Administration (FDA) in 2009 to help control high blood sugar in people with Type 2 diabetes who do not suffer from diabetic ketoacidosis. The drug, manufactured by AstraZeneca, quickly gained popularity because, unlike other medications for Type 2 diabetes, it can control blood sugar without leading to weight gain. Onglyza belongs to a class of drugs known as DPP-4 inhibitors. This DPP-4 inhibitor is an incretin-based therapy that helps the pancreas secrete more insulin and stop the liver from making excess sugar.

When Onglyza first came on the market, it was touted as the "new darling of diabetes treatment" and was said to be the largest breakthrough in research since the discovery of insulin. This blockbuster drug reached $786 million in sales in 2015 and there are huge projections for future earnings.

Linked: Heart Disease And Pancreatic Cancer

However, the drug does not come without issues. Recently, the FDA issued warnings that Onglyza may cause an increase in certain cardiovascular events and could even result in death. In fact, an FDA panel advised that the drug be withdrawn from the U.S. market. In addition to the cardiovascular risks, a 2013 study showed that medications that act in a similar fashion to Onglyza may be linked to a higher risk of pancreatic cancer.

Talk To Us About Your Experience

If you or a loved one has taken Onglyza and suffered heart failure or your loved one passed away, you may have a case for compensation against AstraZeneca. At Reich & Binstock, we are here to help. Contact our lawyers online or call our Houston office at 713-352-7883 or 877-643-3099 toll free for a free and confidential case evaluation.